[
  {
    "date": "2023-12-30",
    "symbol": "ENZN",
    "period": "FY",
    "documenttype": "10-K",
    "documentannualreport": "true",
    "documentperiodenddate": "2023-12-31",
    "documenttransitionreport": "false",
    "entityfilenumber": "001-36435",
    "entityregistrantname": "Enzon Pharmaceuticals, Inc.",
    "entityincorporationstatecountrycode": "DE",
    "entitytaxidentificationnumber": "22-2372868",
    "entityaddressaddressline1": "20 Commerce Drive (Suite 135)",
    "entityaddresscityortown": "Cranford",
    "entityaddressstateorprovince": "NJ",
    "entityaddresspostalzipcode": 7016,
    "cityareacode": 732,
    "localphonenumber": "980-4500",
    "security12gtitle": "Common Stock, $0.01 par value",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "icfrauditorattestationflag": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "entityshellcompany": "false",
    "auditorname": "EisnerAmper LLP",
    "auditorfirmid": 274,
    "auditorlocation": "Philadelphia, Pennsylvania",
    "entitycentralindexkey": 727510,
    "currentfiscalyearenddate": "--12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "amendmentflag": "false",
    "tradingsymbol": "ENZN",
    "cashandcashequivalentsatcarryingvalue": 47012000,
    "otherassetscurrent": 331000,
    "assetscurrent": 47343000,
    "deferredincometaxassetsnet": 359000,
    "assets": 47702000,
    "accountspayablecurrent": 331000,
    "accruedliabilitiescurrent": 108000,
    "dividendspayablecurrent": 1275000,
    "liabilitiescurrent": 1714000,
    "temporaryequitycarryingamountincludingportionattributabletononcontrollinginterests": 42483000,
    "commonstockvalue": 742000,
    "additionalpaidincapitalcommonstock": 73433000,
    "retainedearningsaccumulateddeficit": -70670000,
    "stockholdersequity": 3505000,
    "liabilitiesandstockholdersequity": 47702000,
    "temporaryequityparorstatedvaluepershare": 0.01,
    "temporaryequitysharesauthorized": 40000,
    "temporaryequitysharesissued": 40000,
    "temporaryequitysharesoutstanding": 40000,
    "temporaryequityliquidationpreferencepershare": 1062,
    "preferredstockparorstatedvaluepershare": 0.01,
    "preferredstocksharesauthorized": 2960000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 170000000,
    "commonstocksharesissued": 74214603,
    "commonstocksharesoutstanding": 74214603,
    "othergeneralandadministrativeexpense": 1044000,
    "operatingexpenses": 1044000,
    "operatingincomeloss": -1044000,
    "otherinterestanddividendincome": 2261000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": 1217000,
    "incometaxexpensebenefit": -156000,
    "netincomeloss": 1373000,
    "preferredstockdividendsincomestatementimpact": 1275000,
    "netincomelossavailabletocommonstockholdersbasic": 98000,
    "weightedaveragenumberofsharesoutstandingbasic": 74215000,
    "weightedaveragenumberofdilutedsharesoutstanding": 74215000,
    "sharesoutstanding": 40,
    "dividendscommonstockstock": 1275000,
    "deferredincometaxexpensebenefit": -157000,
    "increasedecreaseinothercurrentassets": -74000,
    "increasedecreaseinotheraccruedliabilities": 15000,
    "netcashprovidedbyusedinoperatingactivities": 1305000,
    "paymentsofdividendscommonstock": 1275000,
    "netcashprovidedbyusedinfinancingactivities": -1275000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 30000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 47012000,
    "temporarystockdividenddeclaration": 1275000,
    "operatinglosscarryforwards": 102500000,
    "percentageofdividendonliquidationpreference": 0.03,
    "initialdividendpershare": 1000,
    "percentageofincreaseinliquidationpreferenceannually": 0.05,
    "dividendspreferredstock": 1275000,
    "preferredstockdividendrateperdollaramount": 31.86,
    "preferredstockliquidationpreferencevalue": 42483000,
    "preferredstockliquidationpreference": 1062,
    "cashequivalentsatcarryingvalue": 46500000,
    "accruedprofessionalfeescurrent": 92000,
    "otheraccruedliabilitiescurrent": 16000,
    "otherliabilityrelatedpartytypeextensibleenumeration": "http://fasb.org/us-gaap/2023#RelatedPartyMember",
    "accruedroyaltiescurrent": 331000,
    "commonstockcapitalsharesreservedforfutureissuance": 9818392,
    "currentstateandforeigntaxexpensebenefit": 1000,
    "currentincometaxexpensebenefit": 1000,
    "deferredfederalincometaxexpensebenefit": -117000,
    "deferredstateandlocalincometaxexpensebenefit": -40000,
    "deferredfederalstateandlocaltaxexpensebenefit": -157000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": 256000,
    "incometaxreconciliationstateandlocalincometaxes": 87000,
    "effectiveincometaxreconciliationexpirationofstatetaxcredits": 1637000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -2136000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 23297000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 11121000,
    "deferredtaxassetsgross": 34418000,
    "deferredtaxassetsvaluationallowance": 34059000,
    "deferredtaxassetsliabilitiesnet": 359000,
    "netoperatinglosscarryforwardslimitationonannualutilization": 1200000,
    "taxcreditcarryforwardlimitationsonuse": "Under the Tax Cuts and Jobs Act, federal net operating losses generated in tax years beginning after December 31, 2017 have an unlimited carryforward period, and the amount of net operating loss allowed to be utilized each year is limited to 80% of taxable income",
    "taxcreditcarryforwardamount": 1600000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "preferredstockliquidationpreferencepercent": 0.03
  },
  {
    "date": "2021-12-30",
    "symbol": "ENZN",
    "period": "FY",
    "documenttype": "10-K",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentperiodenddate": "2021-12-31",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "Enzon Pharmaceuticals, Inc.",
    "entitycentralindexkey": 727510,
    "currentfiscalyearenddate": "--12-31",
    "entityfilenumber": "001-36435",
    "entityincorporationstatecountrycode": "DE",
    "entitytaxidentificationnumber": "22-2372868",
    "entityaddressaddressline1": "20 Commerce Drive (Suite 135)",
    "entityaddresscityortown": "Cranford",
    "entityaddressstateorprovince": "NJ",
    "entityaddresspostalzipcode": 7016,
    "cityareacode": 732,
    "localphonenumber": "980-4500",
    "security12gtitle": "Common Stock, $0.01 par value",
    "tradingsymbol": "ENZN",
    "entityinteractivedatacurrent": "Yes",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "icfrauditorattestationflag": "false",
    "auditorname": "EisnerAmper LLP",
    "auditorfirmid": 274,
    "auditorlocation": "Philadelphia, Pennsylvania",
    "cashandcashequivalentsatcarryingvalue": 47641000,
    "milestonereceivableonroyaltiescurrent": 28000,
    "otherassetscurrent": 85000,
    "assets": 47754000,
    "accountspayablecurrent": 331000,
    "accruedliabilitiescurrent": 72000,
    "liabilitiescurrent": 403000,
    "temporaryequitycarryingamountincludingportionattributabletononcontrollinginterests": 42483000,
    "commonstockvalue": 742000,
    "additionalpaidincapitalcommonstock": 75983000,
    "retainedearningsaccumulateddeficit": -71857000,
    "stockholdersequity": 4868000,
    "liabilitiesandstockholdersequity": 47754000,
    "temporaryequityparorstatedvaluepershare": 0.01,
    "temporaryequitysharesauthorized": 40000,
    "temporaryequitysharesissued": 40000,
    "temporaryequitysharesoutstanding": 40000,
    "temporaryequityaggregateamountofredemptionrequirement": 1062000,
    "preferredstockparorstatedvaluepershare": 0.01,
    "preferredstocksharesauthorized": 2960000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 170000000,
    "commonstocksharesissued": 74214603,
    "commonstocksharesoutstanding": 74214603,
    "royaltyrevenueandmilestones": 701000,
    "revenues": 701000,
    "othergeneralandadministrativeexpense": 1170000,
    "operatingexpenses": 1170000,
    "operatingincomeloss": -469000,
    "othernonoperatingincome": 7000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -462000,
    "incometaxexpensebenefit": 7000,
    "netincomeloss": -469000,
    "preferredstockdividendsincomestatementimpact": 2023000,
    "netincomelossavailabletocommonstockholdersbasic": -2492000,
    "earningspersharebasic": -0.03,
    "earningspersharediluted": -0.03,
    "weightedaveragenumberofsharesoutstandingbasic": 74215,
    "weightedaveragenumberofdilutedsharesoutstanding": 74215,
    "sharesoutstanding": 40,
    "dividendscommonstockstock": -2023000,
    "stockissuedduringperiodsharesnewissues": 40000,
    "increasedecreaseinotheroperatingassets": 23000,
    "increasedecreaseinaccountspayabletrade": 29000,
    "increasedecreaseinotheraccruedliabilities": -38000,
    "netcashprovidedbyusedinoperatingactivities": -501000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -501000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 47641000,
    "accretionofdividendforseriescpreferredstock": 2023000,
    "operatinglosscarryforwards": 103400000,
    "preferredstockdividendpreferenceorrestrictions": "the holders in an amount equal to 3% of the liquidation preference as in effect at such time (initially $1,000 per share). If the dividend is not so paid in cash, the liquidation preference is adjusted and increased annually by an amount equal to 5% of the liquidation preference per share as in effect at such time, that is not paid in cash to the holders on such date.",
    "accruedprofessionalfeescurrent": 61000,
    "otheraccruedliabilitiescurrent": 11000,
    "accruedroyaltiescurrent": 29000,
    "commonstockcapitalsharesreservedforfutureissuance": 9818392,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 25000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 25000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 25000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 25000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 1.31,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 1.31,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 1.31,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P0Y18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P0Y18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P0Y18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "P4Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardminimumexercisepriceaspercentageoffairvalueofstock": 1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexpirationsinperiod": 25000,
    "currentstateandforeigntaxexpensebenefit": 7000,
    "currentincometaxexpensebenefit": 7000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -97000,
    "incometaxreconciliationstateandlocalincometaxes": -28000,
    "effectiveincometaxreconciliationexpirationofstatetaxcredits": 1016000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -884000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 23530000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 13780000,
    "deferredtaxassetsgross": 37310000,
    "deferredtaxassetsvaluationallowance": 37310000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "taxcreditcarryforwardlimitationsonuse": "net operating losses generated in tax years beginning after December 31, 2017 have an unlimited carryforward period, and the amount of net operating loss allowed to be utilized each year is limited to 80% of taxable income",
    "taxcreditcarryforwardamount": 1000000,
    "netoperatinglosscarryforwardslimitationonannualutilization": 468000,
    "preferredstockliquidationpreference": 1062,
    "preferredstockliquidationpreferencepercent": 0.05,
    "preferredstockliquidationpreferencevalue": 2023000,
    "preferredstockcumulativeliquidationvalue": 42483000
  },
  {
    "date": "2020-12-30",
    "symbol": "ENZN",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "ENZON PHARMACEUTICALS, INC.",
    "entitycentralindexkey": 727510,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "security12gtitle": "Common Stock, $0.01 par value",
    "tradingsymbol": "ENZN",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entitysmallbusiness": "true",
    "entityinteractivedatacurrent": "Yes",
    "cashandcashequivalentsatcarryingvalue": 48142000,
    "milestonereceivableonroyaltiescurrent": 7000000,
    "otherassetscurrent": 59000,
    "assetscurrent": 48232000,
    "assets": 48232000,
    "accountspayablecurrent": 302000,
    "accruedliabilitiescurrent": 110000,
    "liabilitiescurrent": 412000,
    "temporaryequitycarryingamountincludingportionattributabletononcontrollinginterests": 40460000,
    "commonstockvalue": 742000,
    "additionalpaidincapitalcommonstock": 78006000,
    "retainedearningsaccumulateddeficit": -71388000,
    "stockholdersequity": 40460000,
    "liabilitiesandstockholdersequity": 48232000,
    "temporaryequityparorstatedvaluepershare": 0.01,
    "temporaryequitysharesauthorized": 40000,
    "temporaryequitysharesissued": 40000,
    "temporaryequitysharesoutstanding": 40000,
    "temporaryequityaggregateamountofredemptionrequirement": 1012000,
    "preferredstockparorstatedvaluepershare": 0.01,
    "preferredstocksharesauthorized": 40000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 170000000,
    "commonstocksharesissued": 74214603,
    "commonstocksharesoutstanding": 74214603,
    "royaltyrevenueandmilestones": 52000,
    "revenues": 22000,
    "othergeneralandadministrativeexpense": 1357000,
    "operatingexpenses": 1357000,
    "operatingincomeloss": -1305000,
    "othernonoperatingincome": 1000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -1304000,
    "incometaxexpensebenefit": 7000,
    "netincomeloss": -1311000,
    "preferredstockdividendsincomestatementimpact": 460000,
    "netincomelossavailabletocommonstockholdersbasic": -1771000,
    "earningspersharebasicanddiluted": -0.03,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 51100000,
    "sharesoutstanding": 40000,
    "dividendscommonstockstock": 460000,
    "stockissuedduringperiodvaluenewissues": 40000000,
    "stockissuedduringperiodsharesnewissues": 40000,
    "increasedecreaseinotheroperatingassets": 28000,
    "increasedecreaseinlongtermreceivablescurrent": -970000,
    "increasedecreaseinaccountspayabletrade": -22000,
    "increasedecreaseinotheraccruedliabilities": 11000,
    "netcashprovidedbyusedinoperatingactivities": -380000,
    "paymentsofstockissuancecosts": 524000,
    "proceedsfromissuanceofcommonstock": 43600000,
    "netcashprovidedbyusedinfinancingactivities": 43076000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 42696000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 48142000,
    "accretionofdividendforseriescpreferredstock": 460000,
    "preferredstockdividendpreferenceorrestrictions": "the holders in an amount equal to 3% of the liquidation preference as in effect at such time (initially $1,000 per share). If the dividend is not so paid in cash, the liquidation preference will be adjusted and increased annually by an amount equal to 5% of the liquidation preference per share as in effect at such time, that is not paid in cash to the holders on such date.",
    "accruedroyaltiescurrent": 302000,
    "patientage": "P1M",
    "periodformilestonepaymentfollowingtriggeringevent": "P3D",
    "cashequivalentsatcarryingvalue": 43600000,
    "offeringcosts": 524000,
    "accruedprofessionalfeescurrent": 92000,
    "otheraccruedliabilitiescurrent": 18000,
    "commonstockcapitalsharesreservedforfutureissuance": 9818392,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 25000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 25000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiod": 17000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 25000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestexpiredandforfeited": 17000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 25000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 1.31,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 1.31,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 1.31,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P1Y18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P1Y18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P1Y18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "P1Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardminimumexercisepriceaspercentageoffairvalueofstock": 1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": 5000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 4600000,
    "currentstateandforeigntaxexpensebenefit": 7000,
    "currentincometaxexpensebenefit": 7000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -274000,
    "incometaxreconciliationstateandlocalincometaxes": -86000,
    "effectiveincometaxreconciliationexpirationofstatetaxcredits": 1039000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -672000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 23398000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 14795000,
    "deferredtaxassetsgross": 38193000,
    "deferredtaxassetsvaluationallowance": 38193000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "operatinglosscarryforwardsyear": "P20Y",
    "operatinglosscarryforwards": 1200000,
    "taxcreditcarryforwardlimitationsonuse": "The Company has remaining R&D credit carryforwards of approximately $14.8 million that expire in the years 2021 through 2029",
    "taxcreditcarryforwardamount": 1000000,
    "operatinglosscarryforwardslimitationonannualutilization": 80,
    "netoperatinglosscarryforwardslimitationonannualutilization": 103000000,
    "preferredstockliquidationpreference": 1012,
    "preferredstockliquidationpreferencepercent": 0.05,
    "preferredstockliquidationpreferencevalue": 460000,
    "preferredstockcumulativeliquidationvalue": 40460000
  },
  {
    "date": "2019-12-30",
    "symbol": "ENZN",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "ENZON PHARMACEUTICALS, INC.",
    "entitycentralindexkey": 727510,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "tradingsymbol": "ENZN",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entitysmallbusiness": "true",
    "entityinteractivedatacurrent": "Yes",
    "cashandcashequivalentsatcarryingvalue": 5446000,
    "milestonereceivableonroyaltiescurrent": 7000000,
    "incometaxesreceivable": 485000,
    "otherassetscurrent": 62000,
    "assetscurrent": 5993000,
    "incometaxesreceivablenoncurrent": 485000,
    "assets": 6478000,
    "accountspayablecurrent": 324000,
    "accruedliabilitiescurrent": 99000,
    "liabilitiescurrent": 423000,
    "commonstockvalue": 442000,
    "additionalpaidincapitalcommonstock": 75690000,
    "retainedearningsaccumulateddeficit": -70077000,
    "stockholdersequity": -70077000,
    "liabilitiesandstockholdersequity": 6478000,
    "preferredstockparorstatedvaluepershare": 0.01,
    "preferredstocksharesauthorized": 100000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 170000000,
    "commonstocksharesissued": 44214603,
    "commonstocksharesoutstanding": 44214603,
    "royaltyrevenueandmilestones": 207000,
    "revenues": 207000,
    "othergeneralandadministrativeexpense": 1180000,
    "operatingexpenses": 1180000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -973000,
    "incometaxexpensebenefit": 6000,
    "netincomeloss": -979000,
    "earningspersharebasicanddiluted": -0.02,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 44215000,
    "sharesoutstanding": 44215000,
    "dividendscommonstockstock": 7959000,
    "increasedecreaseinmilestonesreceivable": -7000000,
    "increasedecreaseinotheroperatingassets": -8000,
    "increasedecreaseinlongtermreceivablescurrent": -970000,
    "increasedecreaseinaccountspayabletrade": -115000,
    "increasedecreaseinotheraccruedliabilities": 21000,
    "netcashprovidedbyusedinoperatingactivities": 6905000,
    "paymentsofdividendscommonstock": 7959000,
    "netcashprovidedbyusedinfinancingactivities": -7959000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -1054000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 5446000,
    "accruedroyaltiescurrent": 324000000,
    "royaltyrevenuemilestones": 7000000,
    "percentageofroyalmilestonesreceivable": 0.5,
    "patientage": "P1M",
    "periodformilestonepaymentfollowingtriggeringevent": "P3D",
    "royaltyperiodfromdateofcommercialsale": "P10Y",
    "accruedprofessionalfeescurrent": 81000,
    "otheraccruedliabilitiescurrent": 18000,
    "royaltyinterestrate": 0.25,
    "commonstockcapitalsharesreservedforfutureissuance": 9818392,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 41787,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 42000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 42000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 42000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 2.93,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 2.93,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 2.93,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P1Y2M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P1Y2M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P1Y2M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "P1Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardminimumexercisepriceaspercentageoffairvalueofstock": 1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": 5000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 4600000,
    "currentstateandforeigntaxexpensebenefit": 6000,
    "currentincometaxexpensebenefit": 6000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -204000,
    "incometaxreconciliationstateandlocalincometaxes": -65000,
    "effectiveincometaxreconciliationexpirationofstatetaxcredits": 416000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -141000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 23030000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 15835000,
    "deferredtaxassetsgross": 38865000,
    "deferredtaxassetsvaluationallowance": 38865000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "operatinglosscarryforwards": 1200000,
    "taxcreditcarryforwardlimitationsonuse": "The Company has remaining R&D credit carryforwards of approximately $15.8 million that expire in the years 2020 through 2029",
    "taxcreditcarryforwardamount": 400000,
    "operatinglosscarryforwardslimitationonannualutilization": 80
  },
  {
    "date": "2018-12-30",
    "symbol": "ENZN",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "2018-12-31",
    "documentfiscalyearfocus": 2018,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "ENZON PHARMACEUTICALS, INC. ",
    "entitycentralindexkey": 727510,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "tradingsymbol": "ENZN",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entitysmallbusiness": "true",
    "cashandcashequivalentsatcarryingvalue": 6500000,
    "milestonereceivableonroyaltiescurrent": 7000000,
    "incometaxesreceivable": 970000,
    "otherassetscurrent": 70000,
    "assetscurrent": 14540000,
    "incometaxesreceivablenoncurrent": 970000,
    "assets": 15510000,
    "accountspayablecurrent": 439000,
    "accruedliabilitiescurrent": 78000,
    "liabilitiescurrent": 517000,
    "commonstockvalue": 442000,
    "additionalpaidincapitalcommonstock": 83649000,
    "retainedearningsaccumulateddeficit": -69098000,
    "stockholdersequity": 14993000,
    "liabilitiesandstockholdersequity": 15510000,
    "preferredstockparorstatedvaluepershare": 0.01,
    "preferredstocksharesauthorized": 100000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 170000000,
    "commonstocksharesissued": 44214603,
    "commonstocksharesoutstanding": 44214603,
    "royaltyrevenueandmilestones": 6918000,
    "revenues": 6918000,
    "othergeneralandadministrativeexpense": 1063000,
    "operatingexpenses": 1063000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": 5855000,
    "incometaxexpensebenefit": 6000,
    "netincomeloss": 5849000,
    "earningspersharebasicanddiluted": 0.13,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 44215000,
    "sharesoutstanding": 44215,
    "increasedecreaseinmilestonesreceivable": 7000000,
    "increasedecreaseinotheroperatingassets": -24000,
    "increasedecreaseinaccountspayabletrade": 214000,
    "increasedecreaseinotheraccruedliabilities": -65000,
    "netcashprovidedbyusedinoperatingactivities": -978000,
    "cashandcashequivalentsperiodincreasedecrease": -978000,
    "royaltyrevenuesfromsalespercentage": -0.02,
    "decreasesofroyaltyrevenues": 280000,
    "accruedroyaltiescurrent": 439000,
    "royaltyrevenuemilestones": 7000000,
    "contractwithcustomerliability": 7000000,
    "percentageofroyalmilestonesreceivable": 0.5,
    "accruedprofessionalfeescurrent": 78000,
    "royaltyinterestrate": 0.25,
    "duetorelatedpartiescurrentandnoncurrent": 225000,
    "commonstockcapitalsharesreservedforfutureissuance": 9818392,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 41787,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 42,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 42,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 42,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 3.11,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 3.11,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 3.11,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P2Y2M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P2Y2M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P2Y2M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": 5000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 4600000,
    "currentstateandforeigntaxexpensebenefit": 6000,
    "currentincometaxexpensebenefit": 6000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": 1229000,
    "incometaxreconciliationstateandlocalincometaxes": 505000,
    "effectiveincometaxreconciliationexpirationofstatetaxcredits": 356000,
    "incometaxreconciliationnondeductibleexpensesharebasedcompensationcost": 248000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -2332000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 22755000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 16252000,
    "deferredtaxassetsgross": 39007000,
    "deferredtaxassetsvaluationallowance": 39007000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "refundoftaxcreditdescription": "In addition, the Act repealed the corporate alternative minimum tax (&#8220;AMT&#8221;) for years beginning after December 31, 2017 and allowed companies with existing alternative minimum tax credit (&#8220;MTC&#8221;) carryforwards as of December 31, 2017 to receive refunds of the credits in tax years after 2017 and before 2022 in an amount equal to 50% (100% in 2021) of the excess MTC over the amount of the credit allowable each year against regular tax liability. ",
    "operatinglosscarryforwards": 1200000,
    "taxcreditcarryforwardlimitationsonuse": "The Company has remaining R&amp;D credit carryforwards of approximately $16.2 million that expire in the years 2019 through 2029",
    "taxcreditcarryforwardamount": 16200000
  }
]